RxDoctor Payments Data

Paul Hicks, MD

Cardiovascular Disease · Elmira, NYNPI 1255366217

Payments from drug & device makers

$3,047in general payments, 2019–2025

Across 55 payments — averaging $55.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Biotronik Inc.$347
  • Kestra Medical Technology Services, Inc.$150
  • Amgen$82
  • Novartis$42
  • Vifor Pharma, Inc.$40
  • plus $224 from 10 others

What the payments were for

  • Travel & lodging$1,54451%
  • Food & beverage$1,43947%
  • Education$642%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,047 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$109,845
Medicare patients
806
Services billed
1,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban439$483,433
XareltoRivaroxaban104$139,046
EntrestoSacubitril/Valsartan93$112,263
JardianceEmpagliflozin70$81,251
Repatha SureclickEvolocumab55$47,168
MultaqDronedarone Hcl32$39,738
Praluent PenAlirocumab32$24,213
BrilintaTicagrelor26$21,489
Repatha SyringeEvolocumab24$17,646
Ranolazine ErRanolazine108$12,513
Metoprolol Succinate598$8,570
Ezetimibe290$5,847
Atorvastatin Calcium398$5,255
Rosuvastatin Calcium288$4,534
Candesartan Cilexetil35$3,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$139,046104 claims
NovartisEntresto$42$112,26393 claims
Boehringer IngelheimJardiance$15$81,25170 claims
AstraZenecaBrilinta$12$21,48926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →